NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy.
about
Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionTreatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionGlucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT.Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy.A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study.Quantification of sudomotor innervation: a comparison of three methods.Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters.Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathyTreatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes.Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial.Peripheral nerve axon involvement in myotonic dystrophy type 1, measured using the automated nerve excitability test.In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment.Bariatric Surgery Restores Cardiac and Sudomotor Autonomic C-Fiber Dysfunction towards Normal in Obese Subjects with Type 2 Diabetes.Clinical neuropathy scales in neuropathy associated with impaired glucose toleranceQuantification of sweat gland innervation: a clinical-pathologic correlation.Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials.Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatmentThe role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study.The role of surgical off-loading to prevent recurrent ulcerations.TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.Assessment scales for the diagnosis of polyneuropathy.Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.Clinical measures in transthyretin familial amyloid polyneuropathy.Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.A comparison of balance control during stance and gait in patients with inflammatory and non-inflammatory polyneuropathy.Axon reflex-mediated vasodilation is reduced in proportion to disease severity in TTR-FAP
P2860
Q24187162-5C7279FB-9A15-4509-937E-E437E89C0A3DQ24201259-F70AD99F-28BA-46A3-A1E4-AC872102E542Q33492801-325A52DA-2CC1-4E73-8AF3-1361F3B538A2Q33854046-F5034AE8-37EC-408E-91DC-150119A7DEEEQ34477951-6C9510EA-CC24-4D31-B776-484F8DAD9696Q34622408-A34C5B11-76D5-4E64-91B4-391F8374AC16Q34637674-B2082DFE-0DAE-431E-9919-2DDB94355310Q34669849-AA936B6E-748A-4C2A-8622-D09779F2D215Q34842230-2FE6D749-3FED-4DAC-B9DF-5FBC6CB447E8Q34978167-EE45C71E-186A-42BF-8B73-DB52C5AD20C3Q35091684-F1EA2644-1F37-4510-A4D4-7851A9297149Q35119383-CD90C1B7-3F62-4E85-A663-2D2D23E1F3C9Q35177035-CD88D589-F739-4899-B9C3-C79B73B069E3Q36005792-83E8B8DC-FBE1-4AAE-B193-831E7B948E5BQ36020817-1CF1E68E-53A9-4B2B-ADC9-5B9A50B2A33FQ37180401-0A853118-B34F-4133-A1C7-9E2610448403Q37275540-63C5D44E-4BB4-455E-8C50-D60157BC231FQ37696931-2CA9B619-A0CF-48AC-AF68-41E03072EE6BQ37708207-1C594BD6-0CB6-47FF-A85C-2405123AA87FQ38266714-08803F00-65A7-40AB-85D0-84DC15B08295Q38708201-F7FC03A7-5229-4167-B586-F5F1B7F58CC8Q38770566-2B0B8920-9D51-4FA7-8423-5EB8C1A21A5DQ39208714-F4881A12-A372-4537-B1A5-90A5B661B8AFQ40166313-BA9E6695-314D-485E-AF94-D622AE5031FBQ45038208-85C5BE6D-D65C-4528-B01E-B228AD52E571Q46339561-30008EED-C6CB-46BA-A60A-1456AE4AC3B7Q55057750-CC3D14FA-6AEB-42D4-B503-882F126EC05BQ58803264-79C71F47-898B-4D1B-9C7B-79BCD07E35BE
P2860
NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@ast
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@en
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@nl
type
label
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@ast
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@en
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@nl
prefLabel
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@ast
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@en
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@nl
P356
P1433
P1476
NIS-LL: the primary measuremen ...... iabetic peripheral neuropathy.
@en
P2093
P356
10.1159/000052074
P478
41 Suppl 1
P577
1999-01-01T00:00:00Z